Literature DB >> 6885174

Pharmacokinetics of amoxicillin and flucloxacillin following the simultaneous intravenous administration of 4 g and 1 g, respectively.

D Adam, P Koeppe, H D Heilmann.   

Abstract

The combination of amoxicillin and flucloxacillin not only widens the spectrum of pathogenic organisms covered by either of the substances alone; synergy has also been observed, particularly against beta-lactamase-producing organisms. For this reason, the possible interaction of these two penicillins regarding their pharmacokinetics was investigated with respect to therapeutic application. The parameters were calculated on the basis of an open two-compartment model. The highest serum levels of amoxicillin from 551 to 1074 mg/l when 4 g were administered alone, and from 403 to 1133 mg/l when administered together with 1 g flucloxacillin. Flucloxacillin concentrations ranged from 118 to 357 mg/l when administered alone, and from 151 to 226 mg/l in the presence of amoxicillin. Thus, there is no significant difference in the peak levels of either substance when given alone or in combination. The pharmacokinetic parameters of both substances basically do not depend on the presence of the other. A slight decrease was observed in the distribution rate of amoxicillin from the central to the peripheral compartment in the presence of flucloxacillin. Its relevance is questionable, however, since the effect was only minor.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6885174     DOI: 10.1007/bf01641294

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  8 in total

1.  Antibacterial activity and synergy, in vitro and in vivo, of a combination of amoxycillin and flucloxacillin.

Authors:  K R Comber; D J Merrikin; R Sutherland
Journal:  Chemotherapy       Date:  1979       Impact factor: 2.544

2.  [Pharmacokinetic and clinical research on a new antibiotic combination (amoxicillin and flucloxacillin in equivalent-weight dose)].

Authors:  F Di Nola; M L Soranzo; G Bosio; N Sachelariu; S Mastroviti
Journal:  Minerva Med       Date:  1977-03-24       Impact factor: 4.806

3.  [Experimental studies of amoxycillin-flucloxacillin combination].

Authors:  S Ripa; M Prenna; C Vitali
Journal:  Antibiotica       Date:  1974-06

4.  [The in vitro and in vivo antibacterial activity of amoxicillin-flucloxacillin combination (1:1 ratio)].

Authors:  G Ravagnan; B Oliva; M Nicoletti; R Piccolomini
Journal:  Antibiotica       Date:  1974-03

5.  A program for non-linear regression analysis to be used on desk-top computers.

Authors:  P Koeppe; C Hamann
Journal:  Comput Programs Biomed       Date:  1980-12

6.  [The antibacterial action of the amoxicillin-flucloxacillin combination].

Authors:  N A Carlone; D Savoia; P Martinetto
Journal:  G Batteriol Virol Immunol       Date:  1975 Jul-Dec

7.  [Pharmacokinetic studies on broad spectrum antibiotic combinations of penicillin and oxacillin in normal volunteers (author's transl)].

Authors:  D Adam; W Bauer; B Seitz; I Voigt
Journal:  Arzneimittelforschung       Date:  1979

8.  A general practice trial of an amoxycillin/flucloxacillin combination (Suprapen) in proven bacterial infections.

Authors:  N A Kritzinger
Journal:  J Int Med Res       Date:  1979       Impact factor: 1.671

  8 in total
  6 in total

1.  Scaling beta-lactam antimicrobial pharmacokinetics from early life to old age.

Authors:  Dagan O Lonsdale; Emma H Baker; Karin Kipper; Charlotte Barker; Barbara Philips; Andrew Rhodes; Mike Sharland; Joseph F Standing
Journal:  Br J Clin Pharmacol       Date:  2018-11-26       Impact factor: 4.335

2.  Population pharmacokinetics at two dose levels and pharmacodynamic profiling of flucloxacillin.

Authors:  Cornelia B Landersdorfer; Carl M J Kirkpatrick; Martina Kinzig-Schippers; Jürgen B Bulitta; Ulrike Holzgrabe; George L Drusano; Fritz Sörgel
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

3.  Inhibition of flucloxacillin tubular renal secretion by piperacillin.

Authors:  Cornelia B Landersdorfer; Carl M J Kirkpatrick; Martina Kinzig; Jürgen B Bulitta; Ulrike Holzgrabe; Fritz Sörgel
Journal:  Br J Clin Pharmacol       Date:  2008-11       Impact factor: 4.335

4.  Penicillinase-resistant antibiotics induce non-immune-mediated cholestasis through HSP27 activation associated with PKC/P38 and PI3K/AKT signaling pathways.

Authors:  Audrey Burban; Ahmad Sharanek; Romain Hüe; Marion Gay; Sylvain Routier; André Guillouzo; Christiane Guguen-Guillouzo
Journal:  Sci Rep       Date:  2017-05-12       Impact factor: 4.379

5.  Pharmacodynamics of Flucloxacillin in a Neutropenic Murine Thigh Infection Model: A Piece of the Puzzle towards Evidence-Based Dosing.

Authors:  Eveline E Roelofsen; Brenda C M de Winter; Heleen van der Spek; Susan Snijders; Birgit C P Koch; Sanne van den Berg; Anouk E Muller
Journal:  Antibiotics (Basel)       Date:  2022-08-03

6.  Characterization of kinetics of human cytochrome P450s involved in bioactivation of flucloxacillin: inhibition of CYP3A-catalysed hydroxylation by sulfaphenazole.

Authors:  Stefan J Dekker; Floor Dohmen; Nico P E Vermeulen; Jan N M Commandeur
Journal:  Br J Pharmacol       Date:  2018-12-26       Impact factor: 8.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.